Abstract
In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.
Copyright © 2020 Elsevier Inc. All rights reserved.
MeSH terms
-
Benzhydryl Compounds / pharmacology
-
Cardiovascular System / drug effects*
-
Cause of Death
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Glomerular Filtration Rate / drug effects
-
Glucosides / pharmacology
-
Glycosides / pharmacology*
-
Hospitalization
-
Humans
-
Kidney / drug effects*
-
Kidney Diseases / drug therapy
-
Randomized Controlled Trials as Topic
-
Sodium-Glucose Transporter 1 / antagonists & inhibitors*
-
Sodium-Glucose Transporter 2 Inhibitors / pharmacology*
Substances
-
Benzhydryl Compounds
-
Glucosides
-
Glycosides
-
SLC5A1 protein, human
-
Sodium-Glucose Transporter 1
-
Sodium-Glucose Transporter 2 Inhibitors
-
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
-
empagliflozin